U.S. markets closed

IRIDEX Corporation Just Reported, And Analysts Assigned A US$5.75 Price Target

Simply Wall St

There's been a major selloff in IRIDEX Corporation (NASDAQ:IRIX) shares in the week since it released its annual report, with the stock down 34% to US$1.74. The results were mixed overall, with revenues slightly ahead of analyst estimates at US$43m. Statutory losses by contrast were6.6% larger than predictions at US$0.64 per share. Following the result, analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see analysts' latest (statutory) post-earnings forecasts for next year.

Check out our latest analysis for IRIDEX

NasdaqGM:IRIX Past and Future Earnings, March 15th 2020

Taking into account the latest results, the current consensus from IRIDEX's twin analysts is for revenues of US$45.1m in 2020, which would reflect a modest 3.8% increase on its sales over the past 12 months. Statutory losses are forecast to balloon 33% to US$0.43 per share. Before this earnings announcement, analysts had been forecasting revenues of US$45.5m and losses of US$0.42 per share in 2020. Although the revenue estimates have not really changed, we can see there's been a earnings per share expectations, suggesting that analysts have become more bullish after the latest result.

Analysts trimmed their valuations, with the average price target falling 28% to US$5.75, with the ongoing losses seemingly weighing on sentiment, despite no real changes to the earnings forecasts.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. For example, we noticed that IRIDEX's rate of growth is expected to accelerate meaningfully, with revenues forecast to grow at 3.8%, well above its historical decline of 0.1% a year over the past five years. Compare this against analyst estimates for the wider market, which suggest that (in aggregate) market revenues are expected to grow 7.7% next year. So although IRIDEX's revenue growth is expected to improve, it is still expected to grow slower than the market.

The Bottom Line

The most important thing to take away is that analysts increased their loss per share estimates for next year. Fortunately, analysts also reconfirmed their revenue estimates, suggesting sales are tracking in line with expectations - although our data does suggest that IRIDEX's revenues are expected to perform worse than the wider market. Analysts also downgraded their price target, suggesting that the latest news has led analysts to become more pessimistic about the intrinsic value of the business.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At least one analyst has provided forecasts out to 2023, which can be seen for free on our platform here.

We also provide an overview of the IRIDEX Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.